ライフサイエンスコーパス: penicillamine

1 ution was feasible using a complexing agent (penicillamine).

2 -year time period in patients treated with D-penicillamine.

3 nitrosoglutathione and S-nitroso-N-acetyl-DL-penicillamine.

4 e/ZnS shells and surface functionalized with penicillamine.

5 4-benzyl-2-oxazolidinones and in the case of penicillamine.

6 sodium nitroprusside and S-nitroso-N-acetyl-penicillamine.

7 ds include DOPA, amphetamine, ephedrine, and penicillamine.

8 failed previous therapy with gold salts and penicillamine.

9 e reacting species is observed with DOPA and penicillamine.

10 ), a cyclized N-protected derivative of D(-)-penicillamine.

11 stability and is inhibited by isoleucine and penicillamine.

12 amine treatment versus 12 receiving low-dose penicillamine.

13 on induced by minocycline, sulfasalazine, or penicillamine.

14 obtained by modification of the amino acid D-penicillamine.

15 icenter trial of high-dose versus low-dose D-penicillamine.

16 MG had recently been provoked by the drug D-penicillamine.

17 (SNP), 1 mmol/L, and S-nitroso-N-acetyl-D-L-penicillamine, 0.1 mmol/L, significantly increased basal

18 imilarly, the NO donor S-nitroso-N-acetyl-dl-penicillamine (1-1000 microm) down-regulated the express

19 hibitors (27 [16.4%]), statins (22 [13.3%]), penicillamine (10 [6.1%]), and tumor necrosis factor inh

20 NO-releasing compounds S-nitroso-N-acetyl-penicillamine (10(-4) mol/L, -34+/-5%) and nitroglycerin

21 D-Penicillamine(2,5)-enkephalin (DPDPE) is a potent opioid

22 oid receptor agonists, deltorphin II, and [D-penicillamine(2,5)]-enkephalin.

23 er previously reported candidate drugs: 2 to penicillamine, 2 to allopurinol, and 1 to sulfasalazine.

24 n of cyclic and topological constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-

25 rosocaptopril, glucose-S-nitroso-N-acetyl-dl-penicillamine-2, and the S-nitroso tripeptide acetyl-Phe

26 onsumption in response to S-nitroso-N-acetyl-penicillamine (-35+/-7%) or nitroglycerin (-16+/-5%) was

27 e rifle PM) with and without the Cu chelator penicillamine, (4) water-soluble components of the rifle

28 By contrast the delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) had

29 th AI and addition of S-nitroso-N-acetyl-d,l-penicillamine (a NO donor) but was not significantly inc

30 Penicillamine (adjusted IRR 2.51, 95% CI 1.29-4.89, P =

31 From [1](-) the related penicillamine and homocysteine complexes were also prepa

32 ed model was verified by exposing worms to D-penicillamine and menadione.

33 small number of case reports also implicate penicillamine and minocycline as agents capable of induc

34 Penicillamine and trientine have teratogenic effects in

35 Food and Drug Administration, which includes penicillamine and trientine.

36 The NO donor SNAP (S-nitroso-N-acetyl-DL-penicillamine) and a soluble guanylyl cyclase agonist (Y

37 s, including H(2)S, 7a-thiospironolactone, L-penicillamine, and captopril, in a time- and concentrati

38 nous nephropathy associated with gold salts, penicillamine, and mercury and use these historical stud

39 g 0.1% (wt/wt) aminoguanidine, pyridoxamine, penicillamine, and nucleophilic compounds NC-I and NC-II

40 onnitrosylated parent molecules, N-acetyl-DL-penicillamine, and reduced gluthatione were without effe

41 ggested that minocycline, sulfasalazine, and penicillamine are associated with antineutrophil cytopla

42 articles was achieved with the assistance of penicillamine as a complexation ligand.

43 ion of pyrogallol and S-nitroso-N-acetyl-D,L-penicillamine, as well as hydrogen peroxide induced a ti

44 and measure transpersulfidation from a bulky penicillamine-based persulfide to a cysteine-based thiol

45 steine differs from the antiarthritis drug D-penicillamine by only two methyl groups on the beta-carb

46 of a series of FSDs (N-acetyl-L-cysteine, D-penicillamine, captopril, L-cysteine, or reduced glutath

47 nds tightly to the active site zinc, while D-penicillamine catalyzes metal removal.

48 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin v

49 cancer therapy with a novel combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a syntheti

50 The antiarthritis drug D-penicillamine (D-PEN) catalyzes zinc(II) transfer from c

51 ts and subjects previously reported in the D-penicillamine (D-Pen) trial.

52 e treated mice with a copper chelator, D-(-)-penicillamine (D-PEN), starting immediately following in

53 In contrast, the antiarthritis drug D-penicillamine, D-PEN, which differs from D-Cys only by t

54 ne and the therapeutic agents penicillamine, penicillamine disulfide, N-acetylcysteine, and captopril

55 -doped quantum dots (Qdots) decorated with D-penicillamine (DPA-MnQdots).

56 olled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective.

57 PBC who had received ineffective therapy (D-penicillamine [DPCA] or placebo) for 5.6 +/- 0.07 years

58 PAECs) with the NO donor, S-nitroso-N-acetyl-penicillamine, dramatically inhibited killing of PAEC ta

59 delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) had no effect on these

60 for 2 days followed by treatment with oral D-penicillamine for 90 days.

61 eceiving placebo; and 3) a 104-week trial of penicillamine for early systemic sclerosis, with 15 unde

62 ize MitoSNO, mitochondria-selective N-acetyl-penicillamine, had no effect on either mtH(2)O(2) genera

63 ine have teratogenic effects in animals, and penicillamine has known teratogenic effects in humans.

64 icacy, whereas the results of therapy with D-penicillamine have been disappointing.

65 Penicillamine, if given before the terminal clinical sta

66 ticipated in the High-Dose Versus Low-Dose D-Penicillamine in Early Diffuse SSc trial.

67 peptides were equally or more effective than penicillamine in trapping AcH in a cell-free system.

68 rug (Thalidomide) and false negative drug (D-penicillamine) in the conventional mouse embryonic stem

69 The NO donor S-nitroso-N-acetyl-DL-penicillamine inhibited caspase-1 activity in cells as w

70 m the TG the NO donor, S-nitroso-N-acetyl-dl-penicillamine, inhibited M-current.

71 and provides insight into the mechanism of D-penicillamine inhibition.

72 d suggest that the conversion of cysteine to penicillamine may partly suppress MeHg formation in cyst

73 fasalazine, auranofin, intramuscular gold, D-penicillamine, methotrexate, and/or azathioprine).

74 ometric detection of cysteine, homocysteine, penicillamine, N-acetylcysteine, and glutathione.

75 amine thiyl radical (S-NAP) from N-acetyl-DL-penicillamine (NAP) and sulfate anion radical (SO3-) fro

76 itrosoglutathione and S-nitroso-N-acetyl-d,l-penicillamine), nitric oxide, oxidized GSH, and hydrogen

77 The effects of other drugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NSAI

78 he nitric oxide donors S-nitroso-N-acetyl-DL-penicillamine or diethyltriamine nitric oxide complex, w

79 utathione, either with S-nitroso-N-acetyl-dl-penicillamine or with S-nitroso-L-cysteine indicate that

80 rs, sodium nitroprusside, S-nitroso-N-acetyl-penicillamine, or 3-morpholinosydnonimine, increased hem

81 -cysteine, glutathione, dimercaptosuccinate, penicillamine, or gamma-glutamylcysteine.

82 itroso-acetyl-DL-penicillamine, S-nitroso-DL-penicillamine, or S-nitroso-glutathione) decreased, in a

83 C3H mice, and in response to Cu chelation by penicillamine (PCA) and dietary supplementation of the m

84 Trientine (TRI) and D-penicillamine (PEN) are used to treat copper overload in

85 ve since cysteine was largely metabolized to penicillamine (PEN) over time at a rate that increased w

86 hylcysteine (Ecy), Thr, Met, D-Cys, Ser, and penicillamine (Pen) produced progressively less efficien

87 iol antioxidants N-acetyl cysteine (NAC) and penicillamine (PEN), respectively.

88 , and homocystine and the therapeutic agents penicillamine, penicillamine disulfide, N-acetylcysteine

89 of a series of N-terminal dipeptides of D(-)-penicillamine, prepared from the synthon 3-formyl-2,2,5,

90 E-selectin expression by S-nitroso-N-acetyl-penicillamine pretreatment and thiol deprivation was ass

91 D-penicillamine protected against advanced glycation end p

92 g; administration of a NO donor, S-nitroso-N-penicillamine, reduced oocyst and infection scores; and

93 oncentration of the NO donor S-nitroso-amino-penicillamine reduces the number of viral particles in a

94 he NO-generating compound S-nitroso-L-acetyl penicillamine resulted in a significant decrease in vira

95 NO donors (S-nitroso-acetyl-DL-penicillamine, S-nitroso-DL-penicillamine, or S-nitroso-

96 e S-nitroso compounds, S-nitroso-N-acetyl-dl-penicillamine, S-nitrosoglutathione, S-nitrosocaptopril,

97 Penicillamine should be used early and adverse prognosti

98 tivity, since GSNO and S-nitroso-N-acetyl-dl-penicillamine significantly and reversibly reduced total

99 dium nitroprusside (SNP) or S-nitroso-acetyl penicillamine (SNAP) (0.25 to 1 mmol/L).

100 eatment with the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) (1 mmol/L for 90 minutes), followed

101 treated with the NO donor S-nitroso-N-acetyl penicillamine (SNAP) at concentrations ranging from 0.3

102 TG or another NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) at doses relevant to the human mode

103 ANP and the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) caused concentration-dependent decr

104 whereas the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) decreased it.

105 osydnonimine (SIN-1), and S-nitroso-N-acetyl-penicillamine (SNAP) on the resting activity (RA) of aff

106 usly by the NO donor S-nitroso-N-acetyl, D,L-penicillamine (SNAP) or endogenously after the exposure

107 ication of the NO-mimetic S-nitroso-N-acetyl-penicillamine (SNAP) or intracellular perfusion with cGM

108 80% in the presence of S-nitroso-N-acetyl-DL-penicillamine (SNAP) or sodium nitroprusside (SNP).

109 mol/L KCl to the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) or to NO is markedly suppressed by

110 The NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) rapidly reduced N-type currents whe

111 ocytes to the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) resulted in a rapid shift in cellul

112 ulated DC to the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) resulted in DC apoptosis.

113 as from a solid NO donor, S-nitroso-N-acetyl penicillamine (SNAP) stored within "coffee pod" style re

114 pplication of H2O2 or S-nitroso-N-acetyl-D-L-penicillamine (SNAP) to evaluate neuroprotection.

115 es for NO, the NO donor S-nitroso-N-acetyl-D-penicillamine (SNAP) was encapsulated within poly(lactic

116 osure to the NO donors S-nitroso-N-acetyl-dl-penicillamine (SNAP), 3-morpholinosydnonimine (SIN-1), o

117 S-Nitroso-N-acetyl-D, L-penicillamine (SNAP), a nitric oxide (NO) donor, and des

118 S-nitroso-N-acetyl-D,L-penicillamine (SNAP), a NO donor, was added after remova

119 S-Nitroso-N-acetyl-D,L-penicillamine (SNAP), a pharmacological NO donor, did no

120 dition to the cultures of S-nitroso-N-acetyl-penicillamine (SNAP), an NO donor, as well as by additio

121 opyridine, SK&F 96365 and S-nitroso-N-acetyl-penicillamine (SNAP), but was decreased by amiloride and

122 e effects of an NO donor, S-nitroso-N-acetyl penicillamine (SNAP), in buffer-perfused Langendorff hea

123 lication of the NO donor, S-nitroso-N-acetyl-penicillamine (SNAP), reproducibly increased the frequen

124 antly more resistant to S-nitro-N-acetyl-d,l-penicillamine (SNAP), sodium nitroprusside (SNP), and hy

125 concentrations of NO donor S-nitroso acetyl penicillamine (SNAP).

126 nitroso-L-glutathione (GSNO) and S-nitroso-N-penicillamine (SNAP).

127 eatment with the NO donor S-nitroso-N-acetyl penicillamine (SNAP).

128 The NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP, 0.1 to 1 mmol/L) oxidized the mitoc

129 In contrast, S-nitroso-N-acetyl-penicillamine (SNAP, 10(-4) mol/L), which releases NO sp

130 reated with nitric oxide donors, S-nitroso-N-penicillamine (SNAP, 25 muM) or diethylenetriamine-NONO

131 he NO-releasing drug S-nitrosyl-N-acetyl-D,L-penicillamine (SNAP; 0-0.5 mM) inhibited dimerization of

132 enerate nitric oxide (S-nitroso-N-acetyl-D,L-penicillamine [SNAP] or (Z)-1-[2-(2-aminoethyl)-N-(2-amm

133 le or nitric oxide donor (S-nitroso-N-acetyl-penicillamine [SNAP] or PAPA NONOATE, 3-[2-Hydroxy-2-nit

134 [SIN-1], 3 mmol/L) or NO (S-nitroso-N-acetyl penicillamine [SNAP]; 3 mmol/L) were analyzed for DNA st

135 ium nitroprusside (SNP) and S-nitroso-acetyl-penicillamine stimulated bile flow and increased both HC

136 otoxin RgIA using a combination of selective penicillamine substitutions together with natural and no

137 copper chelators diethyldithiocarbamate and penicillamine than was catalysis by wild-type CuZnSOD.

138 he nitric oxide donor S-nitroso-N-acetyl-D,L-penicillamine that were restored by administration of su

139 Antecedent D-penicillamine therapy may have been protective against t

140 e numerous reports of such patients stopping penicillamine therapy to protect their fetus from terato

141 iol-vinylsulfone (SV), thiol-acetamide (SA), penicillamine-thiol-maleimide (PM) or penicillamine-thio

142 (SA), penicillamine-thiol-maleimide (PM) or penicillamine-thiol-thiol (PS).

143 cal (GS) from glutathione (GSH), N-acetyl-DL-penicillamine thiyl radical (S-NAP) from N-acetyl-DL-pen

144 Penicillamine treated rifle PM or Cu, slightly reduced l

145 emic sclerosis, with 15 undergoing high-dose penicillamine treatment versus 12 receiving low-dose pen

146 hese defects did not seem to be secondary to penicillamine use, cholestasis, or poor hepatocellular s

147 nine, methyl alpha-glucopyranoside, glucose, penicillamine, valinol, phenylalanine, and tryptophan fr

148 The duration of the use of D-penicillamine was significantly associated with improved

149 ium nitroprusside (SNP) and S-nitroso-acetyl-penicillamine were markedly reduced in endotoxemic IPRL

150 ng molecules, L-cysteine, glutathione, and D-penicillamine, were studied separately, and it was found

151 Similarly, d-penicillamine, which inhibits lysyl oxidase enzymatic ac

152 dified through a single terminal Cys or Pen (penicillamine) with a PEG chain of average length of 2,

153 The SNAP analog N-acetyl-DL-penicillamine (xSNAP; with no NO moiety) had no effect.